In a randomized phase IIa trial, 21 chemotherapy-resistant patients with CRPC received treatment with dendritic cells (DCs) loaded with tumor-associated antigens NY-ESO-1, MAGE-C2, and MUC1. The study demonstrated that immunotherapy using peripheral blood-derived DCs subpopulation is feasible and safe, inducing functional antigen-specific T cells [161]. Here, MUC1 is linked to neoplasm.